| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2009: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2008: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Research Abstract |
1. Randomized controlled trial evidenced that switching treatment to ETV was recommended during at least 2 years' follow-up period in patients treated with LAM for more than 3 years maintaining HBV DNA less than 2.6 log copies/m. 2. Using chimeric mice model, we found new small compounds to inhibit ETV resistant. 3. We found that the low binding affinity for ETV to the DNA binding domains, involving conformationalchange of the binding pocket of HBV RT by the ETVr substitutions, could induce BT. ETV should be considered as a first-line option for nucleoside-naive patients ; however, it is not an optimal therapy for patients with LVDr.
|
